Warren Averett Asset Management LLC Takes $171,000 Position in BioCryst Pharmaceuticals, Inc. (BCRX)

Warren Averett Asset Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,429 shares of the biotechnology company’s stock, valued at approximately $171,000.

Several other large investors also recently modified their holdings of BCRX. Wells Fargo & Company MN increased its holdings in shares of BioCryst Pharmaceuticals by 29.3% during the first quarter. Wells Fargo & Company MN now owns 68,052 shares of the biotechnology company’s stock valued at $324,000 after acquiring an additional 15,403 shares in the last quarter. Northern Trust Corp increased its holdings in shares of BioCryst Pharmaceuticals by 1.1% during the first quarter. Northern Trust Corp now owns 1,188,876 shares of the biotechnology company’s stock valued at $5,671,000 after acquiring an additional 13,044 shares in the last quarter. UBS Group AG increased its holdings in shares of BioCryst Pharmaceuticals by 190.7% during the first quarter. UBS Group AG now owns 291,379 shares of the biotechnology company’s stock valued at $1,390,000 after acquiring an additional 191,157 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in shares of BioCryst Pharmaceuticals by 40.5% during the first quarter. Allianz Asset Management GmbH now owns 231,761 shares of the biotechnology company’s stock valued at $1,105,000 after acquiring an additional 66,783 shares in the last quarter. Finally, State of Wisconsin Investment Board increased its holdings in shares of BioCryst Pharmaceuticals by 79.1% during the second quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock valued at $575,000 after acquiring an additional 44,300 shares in the last quarter. Hedge funds and other institutional investors own 79.82% of the company’s stock.

Several equities research analysts recently commented on the company. Zacks Investment Research cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 15th. ValuEngine raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 12th. Royal Bank of Canada reaffirmed a “buy” rating and set a $9.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 7th. BidaskClub raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, September 28th. Finally, Bank of America raised BioCryst Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research report on Tuesday, July 17th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $9.89.

BioCryst Pharmaceuticals stock opened at $7.09 on Tuesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.25 and a current ratio of 1.25. BioCryst Pharmaceuticals, Inc. has a one year low of $4.25 and a one year high of $8.13. The firm has a market cap of $875.66 million, a P/E ratio of -8.94 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.05. The business had revenue of $12.49 million for the quarter, compared to analysts’ expectations of $3.80 million. BioCryst Pharmaceuticals had a negative return on equity of 107.85% and a negative net margin of 270.95%. As a group, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.87 EPS for the current fiscal year.

In other BioCryst Pharmaceuticals news, CMO William P. Sheridan sold 62,500 shares of the firm’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $7.03, for a total value of $439,375.00. Following the transaction, the chief marketing officer now directly owns 85,713 shares of the company’s stock, valued at $602,562.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas R. Staab II sold 9,850 shares of the firm’s stock in a transaction dated Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the completion of the transaction, the insider now directly owns 140,633 shares in the company, valued at $1,018,182.92. The disclosure for this sale can be found here. Insiders sold 77,144 shares of company stock worth $546,502 over the last three months. Insiders own 4.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Warren Averett Asset Management LLC Takes $171,000 Position in BioCryst Pharmaceuticals, Inc. (BCRX)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/06/warren-averett-asset-management-llc-takes-171000-position-in-biocryst-pharmaceuticals-inc-bcrx.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Read More: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply